CRESCENT-HEALTHCARE
13.3.2023 15:28:44 CET | Business Wire | Press release
The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai. The event, the first dedicated global forum to gather world renowned experts in the region, will focus on the latest advancements in robotic surgery, a rapidly growing field that is revolutionizing healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005505/en/
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention (Photo: AETOSWire)
The Forum will host ministers, senior government officials, as well as healthcare, R&D and investment professionals to discuss the future of robotic assisted surgery, in addition to the UAE’s leading position at the cutting-edge of healthcare.
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention, commented: "As we navigate the challenges of modern healthcare, the UAE is proud to host the Global Robotic MedTech Forum. By embracing technology and innovation, we can further improve patient outcomes and provide more efficient and effective healthcare solutions for all."
Dr. Vipul Patel, President, Society of Robotic Surgery, and one of the world's most experienced robotic surgeons said: "The Forum will provide a unique platform for knowledge exchange and explore innovative solutions that can vastly help improve patient outcomes."
Mr. Hamid Jafar, Chairman of the Crescent Group of Companies, which is hosting the event, said: "The Global Robotic MedTech Forum is an important platform that brings together industry leaders to drive meaningful advancements in the healthcare sector. We are pleased to host this event and look forward to enabling the sharing of insights and knowledge in this exciting field."
Dr. Fred Moll, Founder of Intuitive Surgical and a pioneer of robotic surgery, said: "Honored to be part of the Forum and have the opportunity to share insights on the future of robotic surgery with fellow innovators and industry leaders."
Neeraj Agrawal, Board Member of EndoQuest, said: "This event brings together the best and brightest global minds in the field to the Gulf region, and we are honored to participate."
Kurt Azarbarzin, CEO of EndoQuest, added: "We are excited to present the latest innovations in scarless incisionless robotic surgery deploying flexible robots through natural human orifices."
Eduardo Fonseca, Board Member of XCath, commented: “From advanced imaging and sensors to cutting-edge robotics and AI, the possibilities for enhancing patient outcomes and improving the quality of care are endless. The Gulf region will be at the forefront of the development of groundbreaking technologies that have the potential to transform the healthcare industry."
The Global Robotic MedTech Forum will feature some of the most prominent global figures in the field of robotic surgery including Dr. Chris Thompson, Professor at Harvard University who has been at the forefront of developing and testing new robotic surgical techniques. Dr. Santiago Horgan, the Director of UC San Diego’s Center for the Future of Surgery will also share his insights. The participation of these distinguished experts underscores the importance of the Global Robotic MedTech Forum as a platform for sharing knowledge and advancing the field of robotic medicine.
The Forum will feature keynote speeches from leading experts in the field, interactive panel discussions, and hands-on demonstrations of the latest robotic surgical systems. Attendees will have the opportunity to learn about the latest advancements in the field, and to see first-hand how robotic surgery is rapidly changing the face of healthcare globally.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom